Stem Cell Therapy in Houston, Texas
This page requires review before it goes live. What follows is written to be defensible rather than promotional.
What Is Actually Being Discussed
The term "stem cell therapy" in an orthopedic clinic almost always refers to one of two things:
Bone marrow aspirate concentrate (BMAC) — marrow drawn from the patient's iliac crest and concentrated. It contains a small population of mesenchymal stromal cells alongside platelets and growth factors.
Adipose-derived cellular preparations — cells isolated from the patient's own fat.
Neither is a purified stem cell product, and the mechanism by which either might help is not established. Much of the observed effect may derive from growth factors rather than from any cell engrafting or differentiating into cartilage.
The Regulatory Position
This is the part that governs whether this page can exist at all.
The FDA regulates human cells and tissue products under 21 CFR Part 1271. Autologous products qualify for the limited exception only if they are minimally manipulated and used for a homologous use. Adipose-derived cells expanded in culture, or fat processed and injected into a joint to treat arthritis, fall outside that exception and are considered unapproved drugs and biological products.
The FDA has issued warning letters and pursued injunctions against clinics on precisely these grounds. The FTC has separately taken action against clinics for advertising claims of efficacy that the evidence does not support.
The Evidence Position
There is no adequately powered, well-controlled trial establishing that any autologous stem cell preparation reverses cartilage loss or produces durable benefit in osteoarthritis beyond placebo and the effects of the injection itself.
Small studies report symptom improvement. Larger and better-controlled studies have generally not sustained those findings.
The Recommendation
If Remix Medical offers this service, the page must:
- Name the specific preparation used (BMAC, adipose, other), not the phrase "stem cell therapy"
- Make no claim of cartilage regeneration, disease reversal, or surgery avoidance
- State plainly that the treatment is not FDA-approved for this indication
- State that it is not covered by insurance and disclose the cost
- Present PRP as the better-evidenced regenerative alternative where applicable
If Remix Medical does not currently offer this service, the recommendation is to leave this record unpublished rather than create demand for a treatment the practice does not provide and the evidence does not support.
Next Step
Route to counsel and to Dr. Mantena for a decision on whether this service is offered, under what preparation, and with what claims.